News | Proton Therapy | August 06, 2019

IBA Signs Contract to Install Proton Therapy Center in Kansas

Construction to host IBA’s Proteus One system expected to start later this year

IBA Signs Contract to Install Proton Therapy Center in Kansas

August 6, 2019 — IBA (Ion Beam Applications S.A.) recently signed a contract and received the first payment for a Proteus One solution with The University of Kansas Health System. The contract includes a plan for a possible extension with a second ProteusOne unit in the future. The proton therapy center will be built at the Main Campus of The University of Kansas Health System in Kansas City, Kansas. Construction is anticipated to begin later this year.

The contract includes a long-term operation and maintenance agreement and the typical end-user price for a Proteus One solution, with a maintenance contract between EUR 35 and 40 million. IBA will begin to recognize revenue for the contract in the 2019 financial year.

Bob Page, president and chief executive officer  of The University of Kansas Health System commented, “We are excited to partner with IBA, the world’s leading proton therapy system provider, to bring proton therapy to Kansas City and the region. IBA’s Proteus One represents one of the most advanced solutions to delivering proton therapy. With the first system in place, and the ability to add a second system in the future, patients will be able to stay closer to home to receive the most advanced cancer care available.”

Proteus One is the compact intensity modulated proton therapy (IMPT) solution from IBA, benefiting from the latest technologies. The system is smaller, more affordable, easier to install and to operate.

For more information: www.iba-worldwide.com

Related Content

Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s
High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the h
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Getty Images

News | Women's Health | August 20, 2020
August 20, 2020— For most women with early breast cancer
The results of an online questionnaire of 609 breast cancer survivors in the U.S. suggest that nearly half of patients experienced delays in care during the early weeks of the COVID-19 pandemic.

Getty Images

News | Coronavirus (COVID-19) | August 19, 2020
August 19, 2020 — The...
Smoking is strongly linked to lower use of cancer screening services by women, and more advanced disease once cancer is diagnosed, reveals research published in the online journal BMJ Open.

Getty Images

News | Lung Imaging | August 14, 2020
August 14, 2020 — Smoking is strongly linked to lower use of...
The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite
News | Contrast Media | August 14, 2020
August 14, 2020 — The U.S.